{"data":[{"accessionNo":"0000905148-26-002417","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Parag Shah","reportingCik":null,"personType":"IN,HC","sharesOwned":5790453,"percentOfClass":3.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0000905148-26-002417","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"K2 HealthVentures Equity Trust LLC","reportingCik":null,"personType":"OO","sharesOwned":5790453,"percentOfClass":3.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0000905148-26-002417","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Anup Arora","reportingCik":null,"personType":"IN,HC","sharesOwned":5790453,"percentOfClass":3.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000023","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Raymond Debbane","reportingCik":null,"personType":"IN","sharesOwned":8497822,"percentOfClass":4.7,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000023","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Invus Global Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":7740030,"percentOfClass":4.3,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000023","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Siren, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":7740030,"percentOfClass":4.3,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000023","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Invus Public Equities, L.P.","reportingCik":null,"personType":"PN","sharesOwned":7740030,"percentOfClass":4.3,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000023","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Invus Public Equities Advisors, LLC","reportingCik":null,"personType":"OO","sharesOwned":7740030,"percentOfClass":4.3,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000023","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Avicenna Life Sci Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":757792,"percentOfClass":0.4,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000023","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Ulys, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":757792,"percentOfClass":0.4,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000023","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Avicenna Life Sci Master GP LLC","reportingCik":null,"personType":"OO","sharesOwned":757792,"percentOfClass":0.4,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"Kristina Burow","reportingCik":"0001569248","personType":"IN","sharesOwned":33965419,"percentOfClass":18.7,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Partners XII, LLC","reportingCik":"0001979548","personType":"OO","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"Robert Nelsen","reportingCik":"0001219042","personType":"IN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"Keith Crandell","reportingCik":"0001219039","personType":"IN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Partners X Overage, L.P.","reportingCik":"0001768905","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Fund VII, L.P.","reportingCik":"0001402439","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Fund VIII Overage, L.P.","reportingCik":"0001617237","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Fund X, L.P.","reportingCik":"0001757011","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Fund X Overage, L.P.","reportingCik":"0001757017","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Fund XII, L.P.","reportingCik":"0001906837","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Partners VII, L.P.","reportingCik":"0001544444","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Partners X, L.P.","reportingCik":"0001782583","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Partners XII, L.P.","reportingCik":"0001979765","personType":"PN","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Partners VII, LLC","reportingCik":"0001544443","personType":"OO","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Partners VIII, LLC","reportingCik":"0001616165","personType":"OO","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"ARCH Venture Partners X, LLC","reportingCik":"0001769012","personType":"OO","sharesOwned":33847838,"percentOfClass":18.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"Steven Gillis","reportingCik":"0001229592","personType":"IN","sharesOwned":31526272,"percentOfClass":17.3,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":"640979100","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-30","reportingPerson":"Clinton Bybee","reportingCik":"0001219043","personType":"IN","sharesOwned":3708794,"percentOfClass":2,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-02-13","reportingPerson":"Raymond Debbane","reportingCik":null,"personType":"IN","sharesOwned":8997822,"percentOfClass":5.4,"filedAt":"2026-02-19","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-02-13","reportingPerson":"Invus Global Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":8172814,"percentOfClass":4.9,"filedAt":"2026-02-19","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-02-13","reportingPerson":"Siren, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":8172814,"percentOfClass":4.9,"filedAt":"2026-02-19","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-02-13","reportingPerson":"Invus Public Equities, L.P.","reportingCik":null,"personType":"PN","sharesOwned":8172814,"percentOfClass":4.9,"filedAt":"2026-02-19","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-02-13","reportingPerson":"Invus Public Equities Advisors, LLC","reportingCik":null,"personType":"OO","sharesOwned":8172814,"percentOfClass":4.9,"filedAt":"2026-02-19","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-02-13","reportingPerson":"Avicenna Life Sci Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":825008,"percentOfClass":0.5,"filedAt":"2026-02-19","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-02-13","reportingPerson":"Avicenna Life Sci Master GP LLC","reportingCik":null,"personType":"OO","sharesOwned":825008,"percentOfClass":0.5,"filedAt":"2026-02-19","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0002005369-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-02-13","reportingPerson":"Ulys, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":825008,"percentOfClass":0.5,"filedAt":"2026-02-19","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0000905148-26-000895","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Parag Shah","reportingCik":null,"personType":"IN,HC","sharesOwned":8997035,"percentOfClass":5.01,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0000905148-26-000895","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"K2 HealthVentures Equity Trust LLC","reportingCik":null,"personType":"OO","sharesOwned":8997035,"percentOfClass":5.01,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0000905148-26-000895","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Anup Arora","reportingCik":null,"personType":"IN,HC","sharesOwned":8997035,"percentOfClass":5.01,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"Kristina Burow","reportingCik":"0001569248","personType":"IN","sharesOwned":33958967,"percentOfClass":20.7,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Fund X Overage, L.P.","reportingCik":"0001757017","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Fund XII, L.P.","reportingCik":"0001906837","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Partners VII, L.P.","reportingCik":"0001544444","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Partners X, L.P.","reportingCik":"0001782583","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Partners XII, L.P.","reportingCik":"0001979765","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Partners VII, LLC","reportingCik":"0001544443","personType":"OO","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Partners VIII, LLC","reportingCik":"0001616165","personType":"OO","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Partners X, LLC","reportingCik":"0001769012","personType":"OO","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Partners XII, LLC","reportingCik":"0001979548","personType":"OO","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"Robert Nelsen","reportingCik":"0001219042","personType":"IN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"Keith Crandell","reportingCik":"0001219039","personType":"IN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Partners X Overage, L.P.","reportingCik":"0001768905","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Fund VII, L.P.","reportingCik":"0001402439","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Fund VIII Overage, L.P.","reportingCik":"0001617237","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"ARCH Venture Fund X, L.P.","reportingCik":"0001757011","personType":"PN","sharesOwned":33847838,"percentOfClass":20.6,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"Steven Gillis","reportingCik":"0001229592","personType":"IN","sharesOwned":31526272,"percentOfClass":19.2,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"},{"accessionNo":"0001012975-25-000675","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001885522","issuerName":"Neumora Therapeutics, Inc.","ticker":"NMRA","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-27","reportingPerson":"Clinton Bybee","reportingCik":"0001219043","personType":"IN","sharesOwned":3708794,"percentOfClass":2.3,"filedAt":"2025-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/nmra"}],"updatedAt":"2026-10-24T22:39:29.761Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/nmra","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}